Thioredoxin redox control of cell growth and death and the effects of inhibitors

Chemico-Biological Interactions

Volumn 111-112, Issue , 1998, Pages 23-34

  Powis, Garth ^a   Kirkpatrick, D Lynn ^b   Angulo, Miguel ^a   Baker, Amanda ^a  

^a UNIVERSITY OF ARIZONA   (United States)

^b UNIVERSITY OF REGINA   (Canada)

Author keywords

Apoptosis; Disulfides; Thioredoxin; Thioredoxin reductase

Indexed keywords

2 IMIDAZOLYL DISULFIDE; ANTINEOPLASTIC AGENT; DEXAMETHASONE; ETOPOSIDE; PROTEIN INHIBITOR; STAUROSPORINE; THAPSIGARGIN; THIOREDOXIN; THIOREDOXIN REDUCTASE; UNCLASSIFIED DRUG;

APOPTOSIS; CANCER CELL; DRUG DEVELOPMENT; GENETIC TRANSFECTION; HUMAN; MOUSE; NONHUMAN; OXIDATION REDUCTION REACTION; REVIEW; TUMOR GROWTH;

ANIMALIA;

EID: 0032562519     PISSN: 00092797     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-2797(97)00148-8     Document Type: Article

References (45)

1. Berggren M., Gallegos A., Gasdaska J.R., Gasdaska P.Y., Warneke J., Powis G. Thioredoxin and thioredoxin reductase gene expression in human tumors and cell lines, and the effects of serum stimulation and hypoxia. Anticancer Res. 16:1996;3459-3466.
2. Gasdaska P., Oblong J.E., Powis G. Cloning and expression of thioredoxin (T) cDNA from human colon cancer cells. Identity with ADF and levels of T mRNA in human tumors. Proc. Am. Assoc. Cancer Res. 34:1993;62.
3. Oblong J.E., Gasdaska P.Y., Sherrill K., Powis G. Purification of human thioredoxin reductase: properties and characterization by absorption and circular dichroism spectroscopy. Biochemistry. 32:1993;7271-7277.
4. Gasdaska P.Y., Gasdaska J.R., Cochran S., Powis G. Cloning and sequencing of human thioredoxin reductase. FEBS Lett. 373:1995;5-9.
5. Gasdaska J.R., Gasdaska P.Y., Gallegos A., Powis G. Human thioredoxin reductase gene localization to chromosomal position 12q23→q24.1 and mRNA distribution in human tissue. Genomics. 37:1996;257-259.
6. Gladyshev V.N., Jeang K., Stadtman T.C. Selenocysteine, identified as the penultimate C-terminal residue in human T-cell thioredoxin reductase, corresponds to TGA in the human placental gene. Proc. Natl. Acad. Sci. USA. 93:1996;6146-6174.
7. Tamura T., Stadtman T.C. A new selenoprotein from human lung adenocarcinoma cells: purification, properties, and thioredoxin reductase activity. Proc. Natl. Acad. Sci. USA. 93:1996;1006-1011.
8. Paine G.D., Taylor C.W., Curtis R.A., Lopez M.H.A., Dorr R.T., Roe D., Funk C.Y., Thompson F., Hersh E.M. Human tumor models in the severe combined immunue deficient scid mouse. Cancer Chemother. Pharmacol. 40:1997;209-214.
9. DePalo D., Kinlaw W.B., Zhao C., Engelberg-Kulka H., St. Germain D.L. Effect of selenium deficiency on type I 5′-deodinase. J. Biol. Chem. 269:1994;16223-16228.
10. Berry M.J., Harney J.W., Ohama T., Hatfield D.L. Selenocysteine insertion or termination: factors affecting UGA codon fate and complementary anticodon:codon mutations. Nucl. Acids Res. 22:1994;3753-3759.
11. Low S.C., Berry M.J. Knowing when not to stop: selenocysteine incorporation in eukaryotes. Trends Biochem. Sci. 21:1996;203-207.
12. McCaughan K.K., Brown C.M., Dalphin M.E., Berry M.J., Tate W.P. Translational termination efficiency in mammals is influenced by the base following the stop codon. Proc. Natl. Acad. Sci. USA. 92:1995;5431-5435.
13. Milner J.A. Effect of selenium on virally induced and transplantable tumor models. Fed. Proc. 44:1995;2568-2572.
14. Berggren M., Gallegos A., Gasdaska J., Powis G. Cellular thioredoxin reductase activity is regulated by selenium. Anticancer Res. 17:1997;3377-3380.
15. Baker R.D., Baker S.S., LaRosa K., Whitney C., Newburger P.E. Selenium regulation of glutathione peroxidase in human hepatoma cell line Hep3B. Arch. Biochem. Biophys. 304:1993;53-57.
16. Stadtman T.C. Selenocysteine. Ann. Rev. Biochem. 65:1996;83-100.
17. Holmgren A. Thioredoxin and glutaredoxin systems. J. Biol. Chem. 264:1989;13963-13966.
18. Luthman M., Holmgren A. Rat liver thioredoxin and thioredoxin reductase: purification and characterization. Biochemistry. 21:1982;6628-6633.
19. Gasdaska P.Y., Oblong J.E., Cotgreave I.A., Powis G. The predicted amino acid sequence of human thioredoxin is identical to that of the autocrine growth factor human adult T-cell derived factor (ADF): thioredoxin mRNA is elevated in some human tumors. Biochim. Biophys. Acta. 1218:1994;292-296.
20. Laurent T.C., Moore E.C., Reichard P. Enzymatic synthesis of deoxyribonucleotides VI. Isolation and characterization of thioredoxin, the hydrogen donor from Escherichia coli B. J. Biol. Chem. 239:1964;3436-3444.
21. Matthews J.R., Wakasugi N., Virelizier J.-L., Yodoi J., Hay R.T. Thioredoxin regulates the DNA binding activity of NF-kB by reduction of a disulphide bond involving cysteine 62. Nucl. Acids Res. 20:1992;3821-3830.
22. Grippo J.F., Tienrungroj W., Dahmer M.K., Housley P.R., Pratt W.B. Evidence that the endogenous heat-stable glucocorticoid receptor-activating factor is thioredoxin. J. Biol. Chem. 258:1983;13658-13664.
23. Abate C., Patel L., Rauscher III F.J., Curran T. Redox regulation of fos and jun DNA-binding activity in vitro. Science. 249:1990;1157-1161.
24. Powis G., Oblong J.E., Gasdaska P.Y., Berggren M., Hill S., Kirkpatrick D.L. The thioredoxin/thioredoxin reductase redox system and control of cell growth. Oncol. Res. 6:1994;539-544.
25. Oblong J.E., Berggren M., Gasdaska P.Y., Powis G. Site-directed mutagenesis of active site cysteines in human thioredoxin produces competitive inhibitors of human thioredoxin reductase and elimination of mitogenic properties of thioredoxin. J. Biol. Chem. 269:1994;11714-11720.
26. 73→Ser mutation. Biochem. Pharmacol. 52:1996;1741-1747.
27. Weichsel A., Gasdaska J.R., Powis G., Montfort W.R. Crystal structures of reduced, oxidized and mutated human thioredoxins: evidence for a regulatory homodimer. Structure. 4:1996;735-751.
28. Gasdaska J.R., Berggren M., Powis G. Cell growth stimulation by the redox protein thioredoxin occurs by a novel helper mechanism. Cell Growth Differ. 6:1995;1643-1650.
29. Kitaoka Y., Sorachi K., Nakamura H., Masutani H., Mitsui A., Kobayashi F., Mori T., Yodoi J. Detection of adult T-cell leukemia-derived factor/human thioredoxin in human serum. Immunol. Lett. 41:1994;155-161.
30. Gallegos A., Gasdaska J.R., Taylor C.W., Paine-Murrieta G.D., Goodman D., Gasdaska P.Y., Berggren M., Briehl M.M., Powis G. Transfection with human thioredoxin increases cell proliferation and a dominant negative mutant thioredoxin reverses the transformed phenotype of breast cancer cells. Cancer Res. 56:1996;5765-5770.
31. Baker A., Briehl M., Payne C., Powis G. Thioredoxin, a gene found over-expressed in human cancer, inhibits apoptosis in vitro and in vivo. Cancer Res. 57:1997;5162-5167.
32. Kondo Y., Woo E., Michalska A.E., Choo A.C., Lazo J.S. Metallothionein null cells have increased sensitivity to anticancer drugs. Cancer Res. 55:1995;2021-2023.
33. 2+ fluxes. Proc. Natl. Acad. Sci. USA. 91:1994;6569-6573.
34. Onishi Y., Azuma Y., Sato Y., Mizuno Y., Tadakuma T., Kizaki H. Topoisomerase inhibitors induce apoptosis in thymocytes. Biochim. Biophys. Acta. 1175:1993;147-154.
35. McDonnell T.J., Korsmeyer S.J. Progression from lymphoid hyperplasia to high-grade malignant lymphoma in mice transgenic for the t(14:18). Nature. 349:1991;254-256.
36. Merlino G. Regulatory imbalances in cell proliferation and cell death during oncogenesis in transgenic mice. Semin. Cancer Biol. 5:1994;13-20.
37. Fujii S., Nanbu Y., Nonogaki H., Konishi I., Mori T., Masutani H., Yodoi J. Co-expression of adult T-cell leukemia-derived factor, a human thioredoxin homologue and human papillomavirus DNA in neoplastic cervical squamous epithelium. Cancer. 68:1991;1583-1591.
38. Kawahara N., Tanaka T., Yokomizo A., Nanri H., Ono M., Wada M., Kohno K., Takenaka K., Sugimachi K., Kuwano M. Enhanced co-expression of thioredixin and high mobility group protein 1 genes in human hepatocellular carcinoma and the possible association with decreased sensitivity to cisplatin. Cancer Res. 56:1996;5330-5333.
39. D.L. Kirkpatrick, M. Kuperus, M. Dowdeswell, M. Kunkel, M. Berggren, M. Angulo, Mechanisms of inhibition of the thioredoxin growth factor system by antitumor 2-imidazolyl disulfides, Biochem. Pharmacol. (1998) in press.
40. Kirkpatrick D.L., King K.M., Abu Sa'da I., Kelln R.A., Richardson M.E., Sieman D.W. Effect of a hypoxic tumor cell cytotoxic disulfide on the membrane and DNA of tumor cells in culture. Anticancer Drugs. 3:1992;651-658.
41. Kirkpatrick D.L., Abu Sa'da I., Chernoff W., Kuperus M. Disulfide cytotoxicity under hypoxia. Oncol. Res. 6:1994;545-552.
42. Kunkel M., Kirkpatrick D.L., Johnson G., Johnson J.I., Paul K.T., Myers T., Powis G. Cell line-directed screening assay for inhibitors of thioredoxin reductase signalling as potential anticancer drugs. Anti-Cancer Drug Design. 12:1997;659-670.
43. Powis G., Kirkpatrick D.L., Angulo M., Gasdaska J.R., Powell M.B., Salmon S.E., Montfort W.R. Thioredoxin redox signalling: a novel target for anticancer drug development. Anticancer Drugs. 7(3):1996;121-126.
44. Kirkpatrick D.L., McCabe J., Kuperus M. Stimulation of apoptosis by a redox active disulfide. Proc. Am. Assoc. Cancer Res. 36:1995;41.
45. Kuperus M., Kirkpatrick D.L. Interaction of redox active disulfides with the autocrine growth factor, human thioredoxin. Proc. Am. Assoc. Cancer Res. 36:1995;42.